Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of intravenous WCK 4282 in healthy adults
NL-OMON38943Active, not recruiting
- Sponsor
- Wockhardt
- Start
- Jun 2013
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of cefepime and tazobactam in bacterial disease, urinary tract infection (UTI) and pneumonia (2 arms), sponsored by Wockhardt. Primary endpoints: Pharmacokinetics, Safety and 1 more. Started Jun 2013; status: active, not recruiting.
02
Drugs
cefepimetazobactam
03
Conditions
bacterial diseaseurinary tract infection (UTI)pneumonia
Beyond the preview
Go deeper on NL-OMON38943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38943.